BioLineRx (BLRX) Liabilities and Shareholders Equity (2010 - 2025)

BioLineRx's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $40.9 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 5.14% year-over-year to $40.9 million in Q4 2025; TTM through Dec 2025 was $167.5 million, a 19.42% decrease from a year earlier, with the FY2025 full-year figure at $40.9 million, up 5.14% from the prior year.
• Liabilities and Shareholders Equity climbed to $40.9 million in Q4 2025 per BLRX's latest filing, from $39.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $91.3 million in Q2 2021 and bottomed at $38.9 million in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $64.3 million (2023), against an average of $63.2 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 88.76% in 2021 and plunged 39.14% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $81.4 million in 2021, then dropped by 6.15% to $76.4 million in 2022, then dropped by 16.31% to $63.9 million in 2023, then sank by 39.14% to $38.9 million in 2024, then increased by 5.14% to $40.9 million in 2025.
• Per Business Quant, the three latest BLRX Liabilities and Shareholders Equity figures stand at $40.9 million (Q4 2025), $39.8 million (Q3 2025), and $43.3 million (Q2 2025).